CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

CHICAGO--(BUSINESS WIRE)-- Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants.

The corrected release reads:

XERIS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris’ Board of Directors granted a non-qualified stock option and restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employees under Xeris’ Inducement Equity Plan.

Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The non-qualified stock option is an option to purchase 33,698 shares of Xeris' common stock with a per share exercise price of $8.00, the closing price of Xeris' common stock on the Nasdaq Global Select Market on the grant date. The non-qualified stock option and restricted stock units will vest over a period of three years in equal annual installments and are subject to the employees’ continued employment with Xeris or one of its subsidiaries. All equity awards are subject to the terms and conditions of Xeris’ Inducement Equity Plan and forms of award agreements covering the grants.

About Xeris

Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260702095916/en/

Investor Contact
Allison Wey
Senior Vice President, Investor Relations
[email protected]

Source: Xeris Biopharma Holdings, Inc.

You May Also Be Interested In

• Twenty One Capital Issues Letter from CEO, Raphael Zagury
• Cardinal Infrastructure Group Inc. Reports Second Quarter 2026 Results and Updates 2026 Outlook, Announces Acquisition of Allied Paving
• Blue Moon Metals Acquires 33 Tungsten and Antimony Projects in the Western United States Becoming a Significant U.S. Tungsten, Germanium, Gallium and Antimony Owner in the U.S.